Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abeona TherapeuticsABEO +2.90%32 Days Inventory is 195.41 as of Mar. 2026, which is 67% below its 10-year median of 585.39. GuruFocus rates ABEO with a GF Score™ of 32/100. The stock has 8 warning signs investors should review. Among 638 Biotechnology companies, Abeona Therapeutics ranks worse than 66.61% on this metric.
The historical rank and industry rank for Abeona Therapeutics's Days Inventory or its related term are showing as below:
ABEO'
s Days Inventory Range Over the Past 10 Years
Min: 284.48 Med: 585.39 Max: 585.39
Current: 284.48
During the past 13 years, Abeona Therapeutics's highest Days Inventory was 585.39. The lowest was 284.48. And the median was 585.39.
ABEO's Days Inventory is ranked worse than 66.61% of 638
companies
in the Biotechnology industry
Industry Median: 179.22
vs ABEO: 284.48
Abeona Therapeutics's Days Inventory
increased
from Mar. 2025 (0.00) to Mar. 2026 (195.41).
It might indicate that Abeona Therapeutics's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Abeona Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.47.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Abeona Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.66.
Abeona Therapeutics (NAS:ABEO) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Abeona Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Abeona Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Abeona Therapeutics Days Inventory Related Terms
Abeona Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Abeona Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABEO vs RCKT, UPB, PALI: Days Inventory Comparison
For the Biotechnology subindustry, Abeona Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (ABEO) has a Days Inventory of 195.41 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Abeona Therapeutics and its competitors. This is 67% below median its historical median of 585.39. Over the past decade, Abeona Therapeutics' Days Inventory has ranged from 284.48 to 585.39. According to the industry distribution chart, Abeona Therapeutics ranks #425 out of 638 companies in the Biotechnology industry, placing it in the top 66.6%.
Is Abeona Therapeutics' Days Inventory too high?
Abeona Therapeutics' current Days Inventory of 195.41 is 67% below median its 10-year median of 585.39. Over the past 10 years, this metric has ranged from a low of 284.48 to a high of 585.39. The Biotechnology industry median Days Inventory is 179.22. Abeona Therapeutics' value of 195.41 is 9% above this industry median. Based on the distribution chart, Abeona Therapeutics ranks #425 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Abeona Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' Days Inventory compare to RCKT and UPB?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #425 out of 638 companies for Days Inventory. This places Abeona Therapeutics in the lower half of its industry. The industry median Days Inventory is 179.22. Abeona Therapeutics' value of 195.41 is 9% above this benchmark. Historically, Abeona Therapeutics' own Days Inventory has ranged from 284.48 to 585.39 over the past decade. While the company's 10-year median is 585.39 vs. the industry median of 179.22, Abeona Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 179.22, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abeona Therapeutics's current Days Inventory of 195.41 is 9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Abeona Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 179.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abeona Therapeutics's current Days Inventory is 195.41, which is 67% below median its own 10-year median of 585.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Abeona Therapeutics (ABEO) has a current Days Inventory of 195.41. The current Days Inventory is 195.41, which is 67% below median its 10-year median of 585.39 and 9% above the Biotechnology industry median of 179.22. Abeona Therapeutics' overall GF Score™ is 32/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current Days Inventory is 195.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
32GF Score
Get the complete analysis for ABEO
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABEO has been successfully added to your 
